CD19-targeting chimeric antigen receptor insertion site in T cell genome

The CD19-targeting chimeric antigen receptor insertion site refers to the specific location within the T cell genome where the CAR transgene is integrated during the manufacturing of CAR-T cell therapies (Eyquem et al., 2017, Nature). While early generations of CAR-T cells utilized viral vectors for semi-random integration, contemporary approaches often employ site-specific gene editing tools like CRISPR/Cas9 to target defined loci, most notably the T-cell receptor alpha constant (TRAC) locus (PubMed: 28225754). Targeting the TRAC locus allows for synchronized CAR expression under the control of endogenous promoters and the simultaneous elimination of the native T-cell receptor, which can enhance potency and reduce the risk of graft-versus-host disease (NIH, 2021). This genomic site is critical for ensuring the long-term stability, safety, and efficacy of the engineered T cells as they target CD19-positive malignancies such as B-cell lymphomas and leukemias (StatPearls, 2023). The choice of insertion site can significantly influence the metabolic profile and exhaustion kinetics of the resulting therapeutic T cells.

Other names

TRAC locusT-cell receptor alpha constant locusCAR-T transgene integration siteGenomic safe harborAAVS1 locus

The insertion site serves as the genomic anchor for the CAR transgene, enabling the engineered T cell to express a synthetic receptor that targets CD19-positive cells.